Angehefteter Tweet
It's been real, Twitter.
Moving our lab exploits, science/#breastcancer thoughts, & celebrating wins over to - bsky.app/profile/stover…
English
Daniel Stover, MD, FASCO
4.3K posts
Daniel Stover, MD, FASCO
@StoverLab
Inactive - find me @stoverlab.bsky.social
Columbus, OH Beigetreten Aralık 2016
1.7K Folgt5.2K Follower
Daniel Stover, MD, FASCO retweetet
English
Daniel Stover, MD, FASCO retweetet
English
English
Thrilled to share our new work published in Nature (rdcu.be/eBCM0). We report an exciting new potential therapeutic strategy with a fascinating mechanism of action for cancers with a compromised G1–S cell cycle checkpoint, including SCLC.
nature.com/articles/s4158…
English
Nice work! There is no rationale reason not to screen HER2+ patients for brain metastases.
1) smaller lesions, SRS easier and less radiation necrosis, less morbidity
2) we have two drugs that improve OS in Brain Mets
We don’t need RCTs here…
Elisa Agostinetto@ElisaAgostinett
Out in @TheBreastOnline our survey to physicians👨🏻⚕️& patients👩🏼on screening for brain metastases in pts with #breastcancer🧠 Proud of this international collaboration with colleagues and friends towards better care for pts with brain mets! @OncoAlert doi.org/10.1016/j.brea…
English
Daniel Stover, MD, FASCO retweetet
Training ride this pre @Pelotonia weekend in honor of Stephanie’s #TeamOfHope and to advance care and cures for #BreastCancer at the Stephanie Spielman Center @OSUCCC_James
English
Daniel Stover, MD, FASCO retweetet
Even HP was not tolerable for me as maintenance treatment for HER2+ MBC. The patient community calls Perjeta “poo-jeta” for a reason!
Indefinite T-DxD is not realistic- survivors will have to contend with long term SEs of ADCs (think ❤️& liver fx) #ASCO25 #bcsm
Rani Bansal, MD@DrRaniBansal
Agree! Also if we think in real world for our pts - maintenance HP (esp now we have a subq option) allow pts to not need a port, less frequent labs, less time spent in infusion, more time outside of cancer center Looking forward to hearing pt perspectives! @GRASPtweets @ASCO
English
Is liquid biopsy useful in bone-only metastatic #breastcancer?
Surprise!
✅Pts w bone-only disease are just as likely to have detectable ctDNA
✅ctDNA tumor fraction remains prognostic in bone-only setting
link.springer.com/article/10.100…
@FoundationATCG @OSUCCC_James @OhioStateMedOnc
English
@FedExHelp Thank you. Sent DM. Please help me get these where they need to go!
English
Hi, this is Shairene. I am sorry to hear that you were not able to receive your shipment yet. I would love to help you with this and check the latest movement of the package. Please DM your complete name, full delivery address, tracking number, phone number and email address. Thank you. x.com/messages/compo…
English
Informed by @FedEx @FedExHelp that *irreplaceable* shipment of plasma donated by metastatic #breastcancer patients for #cancerresearch are sitting in same city as delivery address - but not delivered till tomorrow.
3 days for overnight dry ice shipment is unacceptable @Fedex.
English
We are very excited to welcome @KimrynRathmell as our next CEO @OSUCCC_James!
Brilliant physician-scientist, talented administrator, dedicated mentor - we are so excited for what is to come!
Kimryn Rathmell@KimrynRathmell
I’m honored to serve as the next CEO of the @osuccc_james & look forward to joining my new Buckeye colleagues at @osuwexmed & @ohiostate to take bold steps to advance the future of oncology across Ohio & nationally. Check out my LinkedIn to learn more. go.osu.edu/C4w3
English
Daniel Stover, MD, FASCO retweetet
Incredible to have @StoverLab giving a keynote lecture at the Harvard Breast and Gynecologic Cancer Symposium- what a thoughtful and practical approach to translational research in breast cancer
English
Daniel Stover, MD, FASCO retweetet
The @df_hcc Breast & Gynecologic Cancer Symposium started off with the J. Dirk Iglehart, M.D., Visiting Scholar Lecture given by Dr. Daniel Stover (@StoverLab) who discussed Translational Cancer Research: Data is the Answer and the Question.
dfhcc.harvard.edu/events/dfhcc-b…
English
English
Excited to announce the funding of the first ever @NIH Program Project Grant (PPG) in Cardio-Oncology! Terrific collaboration between @UCSFCardiology & @StanfordCVI! @Joseph_C_Wu #CardioOnc
ucsf.edu/news/2024/11/4…
English
English
Congrats to Isaac Harris, PhD, & Nicole O'Dell, PhD, MLS, for receiving Wilmot Community Outreach and Engagement Innovator Awards!
They were recognized for working with the Community Cancer Action Council & striving to bring together community with Wilmot research & education.
English
English
Option in the 1L metastatic setting for patients whose tumors harbor PIK3CA mutations; need to test earlier especially for those who have recurrence or within 12 months of adjuvant ET @MSKCancerCenter @MSK_DeptOfMed
OncoAlert@OncoAlert
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer Just Out on @NEJM Inavolisib, a potent and selective inhibitor of the PI3Kα isoform, was evaluated in combination w/ palbociclib💊 and fulvestrant in a phase 3⃣ trial for patients with PIK3CA-mutated🧬, hormone receptor-positive, HER2-negative advanced #BreastCancer Compared to placebo, the inavolisib group showed a significantly longer progression-free survival (15.0 vs. 7.3 months), with a higher objective response rate (58.4% vs. 25.0%). However, the inavolisib group experienced more toxic effects, including neutropenia, hyperglycemia, and stomatitis. Despite this, discontinuation due to adverse events was relatively low at 6.8% in the inavolisib group. nejm.org/doi/full/10.10… Oncoalert #BreastCancer Faculty @CristinaSaura3 @dejuric @LoiblSibylle @KalinskyKevin @a_musolino @LiuCluster @jhaveri_komal OncoAlert Breast Cancer Faculty @matteolambe @E_de_Azambuja @prat_aleix @DrSGraff @jesusanampa @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @JaniceTNBCmets #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @lungoncdoc @bavilima @realbowtiedoc @Erman_Akkus @DrFMartinelli @Lucarecco @heinrich_kat @niklas_kluemper
English
Daniel Stover, MD, FASCO retweetet
Our Early Drug Development Unit it’s a brand new facility advancing the knowledge of new drugs and giving patients access to clinical trials. Great team from doctors, nurses, lab, research to administration working for our patients. @OSUCCC_James @OhioStateMedOnc @OSUWexMed
English